[Comment] Increased extent of neurosurgical resection in IDH-mutated glioma: issues for translation to standard practice Improved molecular classification of glioma has allowed identification of defined patient subgroups with prolonged survival outcomes and the potential for alternative management plans.1,2 Specifically for newly diagnosed patients with lower grade glioma (WHO grade 2–3) harbouring the IDH mutation, initial neurosurgical decision making can be complex due to the balance of optimising disease control and avoidance of long-term neurological morbidity.… The Lancet Oncology November 26, 2025 Original source
[Comment] Evolution in rectal cancer management Non-operative management after a clinical complete response following neoadjuvant treatment in rectal cancer, often referred to as opportunistic non-operative management rather than intentional non-operative management (ie, up-front treatment for early-stage patients with the aim of non-operative management), is increasingly being implemented. Provided meticulous follow-up, data suggest that non-operative management is feasible, safe, and associated with favourable overall survival.1 However, challenges… The Lancet Oncology November 26, 2025 Original source
[Comment] Of surrogate endpoints, shortcuts, and safety Adjuvant and neoadjuvant systemic drug therapy prevents recurrence and premature death in patients with breast cancer by treating undetectable micrometastatic disease.1 For less toxic treatments, prevention of metastases alone can justify therapy because patients should experience improved quality of life without metastases, but for more toxic or risky treatments improved overall survival might be required.2 When improving overall survival is… The Lancet Oncology November 26, 2025 Original source
[Comment] Adjuvant capecitabine in early-stage triple-negative breast cancer? Yes, but for whom? In The Lancet Oncology, Jing Yuan and colleagues present updated results from the SYSUCC-001 trial, evaluating extended adjuvant endocrine therapy with a year of twice daily (metronomic) capecitabine compared with observation in early-stage triple-negative breast cancer following standard chemotherapy.1,2 This post-hoc analysis includes data from 420 of the 434 patients in the trial. The findings confirm the benefit of extended… The Lancet Oncology November 26, 2025 Original source
[Comment] Pirfenidone: a new option for radiation-induced lung injury? Radiation-induced lung injury is a clinically significant complication induced by thoracic radiotherapy.1 10–20% of patients present with signs of radiation-induced lung injury, which vary widely according to grade and type of cancer and duration of treatment.2 The Lancet Oncology November 26, 2025 Original source
[Comment] Defining eligibility for lung cancer screening based on individual risk Implementation of lung cancer screening is advancing globally, and most countries use categorical eligibility criteria resembling those from randomised low-dose CT screening trials. For example, the US Preventive Services Task Force (USPSTF) requires age 50–80 years, at least 20 pack-years smoked, and 15 years or less of cessation. However, beginning in 2013, studies suggested that defining eligibility using individual lung… The Lancet Oncology November 26, 2025 Original source
[Editorial] Making prostate cancer screening fit for purpose Prostate cancer incidence is predicted to double to 2·9 million cases by 2040. Men diagnosed with clinically significant prostate cancer have many effective treatment options, but questions remain regarding the best diagnostic pathway. The value of population-based prostate cancer screening using a prostate-specific antigen (PSA) threshold, for example, is long-debated and is not universally recommended because of concerns around the… The Lancet Oncology November 26, 2025 Original source
Development and Evaluation of an Optimal Machine Learning Model for Predicting Nutritional Risk in Nasopharyngeal Carcinoma Patients: A Cross-Sectional Study . <br /> Nutrition and Cancer Journal November 25, 2025 Original source
Will AI Write the Next "Chapter" in Literature Reviews? In the last ten years, the rapid expansion of oncology knowledge, with numerous new therapeutic targets, drug approvals, early interventions, along with an exponentially increased number of clinical trials, have dramatically complexified treatment algorithms and been responsible for a significant rise in cancer-related survival rates [1,2]. International guidelines often struggle to keep pace with the rapid advancements of discoveries and… Annals of Oncology November 25, 2025 Original source
Macrophage CCL7 promotes resistance to immunotherapy for colorectal cancer by regulating the infiltration of macrophages and CD8+ T cells Background <p>Immune checkpoint inhibitors (ICIs) have been proven to be one of the most promising and effective immunotherapies; however, their efficacy in colorectal cancer (CRC) remains significantly limited. Therefore, understanding the mechanism of resistance to ICIs therapy in CRC patients is of great significance for the development of new anti-tumor immunotherapy targets.</p> Methods <p>Ccl7 myeloid cell-specific knockout mice and MC38… Journal for ImmunoTherapy of Cancer November 25, 2025 Original source
Development of a novel 18F-labeled radiotracer targeting granzyme B for imaging early tumor responses to immunotherapy Background <p>Immunotherapy has emerged as a promising avenue for malignant tumors treatment, but methods to validate its in vivo antitumor activity remain limited. Granzyme B, a key mediator of immune-mediated cell death, is a potential biomarker for assessing immunotherapy efficacy. This study aimed to develop a radiotracer with high sensitivity and specificity for in vivo imaging of granzyme B.</p> Methods… Journal for ImmunoTherapy of Cancer November 25, 2025 Original source
HMGA2 links morphological evolution and microenvironment dynamics to systemic therapy response in clear cell renal cell carcinoma Background <p>Clear cell renal cell carcinoma (ccRCC) exhibits significant heterogeneity due to morphological changes and tumor microenvironment dynamics, influencing systemic therapy responses. While the role of high-mobility group AT-hook 2 (HMGA2) in tumor progression has been implicated in other cancers, its significance in ccRCC remains unclear. This study investigates the role of HMGA2 in these processes and its clinical impact.</p>… Journal for ImmunoTherapy of Cancer November 25, 2025 Original source
Targeting macropinocytosis for cancer therapy <p>Nature Reviews Cancer, Published online: 24 November 2025; <a href="https://www.nature.com/articles/s41568-025-00892-x">doi:10.1038/s41568-025-00892-x</a></p>Macropinocytosis enables cancer cells to absorb nutrients from their environment, supporting growth and therapy resistance. In this Review, Tang, Wang, Kroemer and Kang outline its regulatory mechanisms, implications for treatment strategies and potential as a target for enhancing therapeutic efficacy in oncology. Nature Reviews Cancer November 24, 2025 Original source
What is the Difference Between a Screening and a Diagnostic Mammogram? <p>Mammograms are one of the best tools you can use to stay on top of your breast health. A mammogram is one of the most effective tests for catching breast cancer early.  A mammogram is performed with an X-ray machine that compresses the breast to take an image. This machine can be used for two ... <a class="read-more" href="https://blog.dana-farber.org/insight/2025/11/what-is-the-difference-between-a-screening-and-a-diagnostic-mammogram/" title="What… Dana-Farber Cancer Institute November 24, 2025 Original source
Standardizing Time-to-Event Reporting in Single-Arm BCG-Unresponsive Registration Trials: A Case for Kaplan-Meier In 2018, the FDA issued guidance on drug development for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC), prompting a wave of single-arm registration trials that introduced new agents, including immune checkpoint inhibitors, intravesical gene therapy, cytokine agonists, and drug-eluting devices.1–6 Interpretation of these studies, however, has been hampered by heterogeneity in time-to-event endpoint reporting. Annals of Oncology November 24, 2025 Original source
ROME trial Wasn't Built in a Day: The Decade-Long Journey to Randomized Evidence in Precision Oncology Precision oncology has long promised to transform cancer treatment by matching patients to therapies based on their tumor's molecular profile. Despite regulatory approvals for tumor-agnostic biomarkers including microsatellite instability, NTRK and RET fusions, and BRAFV600 mutations skepticism has persisted about whether genomically-guided therapy truly outperforms standard care[1]. The ROME trial now provides the answer[2]. Annals of Oncology November 22, 2025 Original source
Letter to the Editor: Reevaluating Diet–microbiota Interactions in Colorectal Carcinogenesis . <br /> Nutrition and Cancer Journal November 22, 2025 Original source
Letter to the Editor: Revisiting the Impact of Obesity on Cancer-Specific Survival in Rectal Cancer—Clinical and Translational Implications . <br /> Nutrition and Cancer Journal November 22, 2025 Original source
Effectiveness of Nutritional Screening Tools in Predicting the Impact of Malnutrition on Hospital and Intensive Care Unit Stay . <br /> Nutrition and Cancer Journal November 22, 2025 Original source
Oncolytic virus-induced IL-1{beta}+ monocyte-IL-6+ CAF axis suppresses dendritic cell-mediated antitumor immunity in pancreatic cancer Background <p>Pancreatic ductal adenocarcinoma (PDAC) is characterized by a profoundly immunosuppressive tumor microenvironment, which features a dense desmoplastic stroma enriched with cancer-associated fibroblasts (CAFs) that collectively impede the efficacy of immunotherapies. Although oncolytic viruses (OVs) have demonstrated promising potential in eliciting antitumor immunity, the mechanisms by which stromal components modulate OV efficacy remain poorly understood.</p> Methods <p>To investigate the interplay… Journal for ImmunoTherapy of Cancer November 22, 2025 Original source